English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Please cite this article as: Reguero-del Cura L, Durán-Vian C, de Quintana-Sancho A. FR-Mesoterapia con dutasterida, una futura alternativa para el tratamiento de la alopecia androgenética. Actas Dermosifiliogr. 2020;111:419--420. ∗ Corresponding author. E-mail address: leandrareguero@yahoo.com (L. Reguero-del Cura). The first clinical trial evaluating the efficacy and safety of intradermal injection of 0.05% dutasteride solution in patients with male AGA was published in 2009. Fourteen of the 28 patients received a total of 7 injections, separated by at least 1 week, of a 2-mL dutasteride solution. Increased hair density was reported in 92.9% of patients in the dutasteride group, but only 7.1% in the placebo group. No significant differences in adverse effects were observed between groups. A 2013 study by Sobhy et al compared the efficacy of 0.005% dutasteride alone, 0.05% dutasteride in a dexpanthenol, biotin, and pyridoxine solution, and 0.9% physiological serum (control group), administered in 9 separate injections to 90 patients with male AGA. The authors reported a significant increase in the number of follicles in anagen phase in the group that received 0.05% dutasteride in the vitamin solution. However, the possibility that the adjuvants contributed to the differences between groups cannot be ruled out. Another clinical trial published in 2013 compared the efficacy of 2 mL of 0.05% dutasteride in a dexpanthenol, biotin, and pyridoxine solution with that of physiological saline in 126 women with female AGA. Participants underwent 12 mesotherapy sessions over a period of 16 weeks. Improvements were observed in 62.8% of dutasteride-treated patients as compared with 17.5% of patients in the control group.